STAT

Yes! Through Herm.io, you can unlock personalized STAT deals and exclusive rewards based on your shopping profile. Instead of the same generic discounts everyone gets, your profile shows STAT that you're a valuable shopper — and they respond with better offers. Sign up for free to see what exclusive rewards are available for you.

STAT offers products across the following categories: Apps & Subscriptions, Streaming Services, Podcasts, Magazines & Newspapers. Browse their full range on their official website or explore exclusive offers for STAT products on Herm.io.

You can reach STAT through their official website at https://statnews.com for support options.

Sign up for free on Herm.io, connect your shopping history, and follow STAT. Your shopping profile helps STAT see you're a valuable customer, unlocking personalized discounts, store credit, and exclusive merchandise. The more you engage and prove your loyalty, the better your rewards become.

STAT+ is a premium subscription service offering exclusive biotech, pharma, and life sciences analysis that free publications don't provide. Industry professionals report it's valuable for staying ahead on regulatory changes, clinical trial data, and investment trends. The cost is typically justified for those who rely on timely, in-depth health industry intelligence for their work. Free content is available, but STAT+ subscribers get deeper analysis and early access to breaking stories.

STAT focuses on investigative journalism and in-depth analysis with a premium subscription model, while FiercePharma and BioPharma Dive are free industry newsletters with quicker news updates. STAT is known for original reporting and longer-form stories about science, policy, and healthcare. FiercePharma tends to cover more business deals and marketing angles. BioPharma Dive offers concise daily summaries. STAT is generally considered more journalistic, while the others are more trade publication oriented.

STAT can be challenging for complete beginners as it assumes some industry knowledge and uses technical terminology. However, it's excellent for people transitioning into biotech, pharma, or healthcare roles who want to quickly get up to speed on current issues and industry dynamics. The free articles and newsletters provide a good starting point, while STAT+ might be more appropriate once you're established in the field and need deeper analysis.

Both STAT and Endpoints News are premium biotech and pharma publications, but STAT covers broader health and medicine topics including public health, policy, and science. Endpoints focuses more narrowly on drug development, clinical trials, and biotech business news. STAT is known for investigative pieces and science journalism, while Endpoints emphasizes breaking news and market-moving information for investors and executives. Both require paid subscriptions for full access.

STAT primarily targets biotech and pharmaceutical industry professionals, healthcare investors, medical researchers, policy makers, and clinical professionals. The publication is designed for people who work in or closely follow the life sciences industry and need detailed, accurate reporting on drug development, FDA decisions, clinical trials, and healthcare policy. It's also read by journalists, academics, and anyone seeking authoritative coverage of health and medicine beyond mainstream news outlets.

STAT offers a selection of free articles, newsletters, and podcasts, but many in-depth reports and breaking news stories are restricted to STAT+ subscribers. The paywall typically allows a few free articles per month before requiring a paid subscription for full access.

STAT primarily operates through its website and email newsletters rather than a dedicated mobile app. The website is mobile-responsive and works well on smartphones and tablets for reading articles and accessing subscriber content.

STAT is widely regarded as a credible source with experienced health and science journalists who fact-check their reporting and cite primary sources. The publication has won journalism awards and is frequently cited by major media outlets, researchers, and industry professionals for its accuracy and investigative work.

STAT offers several free daily and weekly newsletters covering topics like biotech, public health, and FDA decisions, plus premium newsletters exclusively for STAT+ subscribers. Popular free options include the Morning Rounds daily briefing, while paid subscribers get access to specialized briefings on specific therapeutic areas and policy developments.

STAT covers some clinical topics and medical research relevant to physicians, but focuses more on drug development, industry trends, and healthcare policy rather than clinical practice guidelines. Physicians looking for practice-focused medical news may find publications like Medscape or NEJM Journal Watch more directly applicable to patient care.